-0.46% $56.79
America/New_York / 16 mai 2024 @ 14:12
Live Signal Incyte Corp
Sell @ $56.77
Issued: 16 mai 2024 @ 13:13 / Return: 0.04%
Previous Signal: buy @ 15 mai 2024 @ 13:42 - Return: -0.7 %
$1 invested is now $1.07 or 7.30 % *
(* In 14 weeks 2 days 3 hours 40 minutes and 34 seconds .)
Dividend: X | Profitable: Y | Good Trading Volume: Y
About Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Last live signals for Incyte Corp
The Live signals presented on this page help you to determine when to buy or sell Incyte Corp. The signals has upwards to 1 minute delay and like all signals there is an given chance for error or mistakes. The signals are not definite and stockinvestor.us hold no responsibility for any action taken upon these signals as clearly described in the TOS. The signals is based on technical analysis based on a wide range of indicators.
Right now there is a sell signal from rsi14 in the stock and a buy is not recommended
Answer last updated: 16 mai 2024 @ 14:12
We cannot find any recorded dividends paid in our systems.
Yes, the consensus target for Incyte Corp is $85.64, which is $28.85, or 50.80 % above today's price. The analysts has low target of $52.00 and a high target of $136.00
We cannot find data for Incyte Corp 10 years ago, but if you had invested on Friday 17th of May 2019 when price was $77.20 you would have made a loss of $0 per share or -26.37 %
Yes, the average daily trading liquidity for Incyte Corp is $2 005 832 . You should therefore be able to get in and out of your positions relatively fast.
Incyte Corp has no real debt which is good in periods of high inflation. With a high cash flow to debt ratio of 21.95 the company's ability to pay of the debt is good. Incyte Corp has a good net profit margin of 19.78% and should have high tolerances against inflation as the profit margin can be reduced to maintain market positions and overall sales.
We have calculated the inflation risk for Incyte Corp to be [0.1 of 1]
US inflation for March 2024 was 0.38%. Over last 12 months the US inflation is 3.48%. The 10 year treasury yield that indicate the future interest level is currently 4.36 and is up 0.47 over last 30 days.